ArticleFrontiers in genetics2026
Single-cell transcriptomic profiling uncovers key molecular signatures in glioma pathogenesis.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioma represents the most prevalent and lethal primary malignant tumor of the central nervous system, characterized by remarkable cellular heterogeneity and poor prognosis. Comprehensive characterization of glioma at single-cell resolution is essential for identifying novel therapeutic targets and improving patient outcomes. Methods: We performed comprehensive single-cell RNA sequencing (scRNA-seq) analysis on glioma samples obtained from the Gene Expression Omnibus (GEO) database. Advanced computational approaches including principal component analysis (PCA), uniform manifold approximation and projection (UMAP), t-distributed stochastic neighbor embedding (t-SNE), and differential expression analysis were employed to characterize cellular heterogeneity. Gene co-expression network construction and pathway enrichment analysis were conducted to identify functional modules. Candidate biomarkers were validated using quantitative real-time PCR (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA) in GL261 glioma cells, C8-D1A normal glial cells, and intervertebral disc nucleus pulposus cells. Results: Quality control analysis revealed high-quality single-cell data with median gene counts of 5,437 and UMI counts of 14,207 per cell. A total of 4,753 highly variable genes were identified, and 22 distinct cellular clusters were delineated using the Louvain algorithm. PCA loading analysis identified key contributing genes including cell cycle regulators (CDK1, TOP2A, BIRC5), immune-related genes (C1QA, C1QB, HLA-DRB6), and neural lineage markers (MOBP, MAG, GJB1). Cell type annotation identified seven major populations: astrocytes, oligodendrocytes, microglia, neural stem cells, OPC/immature neurons, pericytes, and T cells. Differential expression analysis uncovered 847 upregulated and 652 downregulated genes (|log Conclusion: This comprehensive single-cell transcriptomic analysis successfully characterized the cellular heterogeneity of glioma, identifying distinct cell populations and molecular signatures. PLP1, FTH1, and GM42418 were validated as potential molecular biomarkers, providing novel insights into glioma pathogenesis and potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.